A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
SUMMARY
N/A
COH Protocol Number : 14179
ClinicalTrials.gov Number : NCT01526928
Principal Investigator : Reckamp, Karen M.D.
Sponsor : Clovis Oncology, Inc.
BRIEF ELIGIBILITY CRITERIA :
Eligible Ages : >=18
Gender : Either
Minimum Performance Status : ECOG/SWOG:1
Treatment Intent : Non-Adjuvant treatment
Prior Chemotherapy :
Brain Metastases :
Measurable Disease :
